ArticleItalian journal of pediatrics2026
Clinical characteristics in antibody-positive pediatric patients with immune-mediated necrotizing myopathy.
Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the clinical characteristics and therapeutic strategies of childhood immune-mediated necrotizing myopathy (IMNM) and to provide evidence for clinical diagnosis and management.
methodsThis single-center retrospective study analyzed the clinical data of 10 children diagnosed with antibody-positive IMNM at the Children's Medical Center, Xiangya Hospital, Central South University, from January 2016 to May 2025. The onset features, clinical manifestations, laboratory findings, muscle magnetic resonance imaging (MRI) characteristics, treatment modalities, and prognosis were summarized.
resultsAmong the 10 patients, 4 were male and 6 were female, with a median age at onset of 5.5 years (range: 3-16 years). The main clinical manifestations included symmetric proximal muscle weakness (100%) and cutaneous manifestations (50%, including Gottron's sign and periorbital rash). Creatine kinase (CK) levels were markedly elevated, with a median of 3988.5 U/L (range: 2080-13524 U/L). Muscle MRI revealed edema or fatty infiltration in the thigh muscles. Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies were detected in 4 patients (40%), and anti-signal recognition particle (SRP) antibodies in 6 patients (60%). Electromyography (EMG) showed myopathic changes in all tested cases (8/10 patients). Muscle histopathology was available for one patient, demonstrating myofiber necrosis, regeneration, and inflammatory cell infiltration. All patients received glucocorticoid therapy, combined with oral methotrexate. Additionally, 5 patients were treated with rituximab, and 9 patients received intravenous immunoglobulin (IVIG). During follow-up, 2 patients achieved complete remission, 1 patient showed partial remission, 3 patients exhibited no significant remission, and 4 patients experienced relapse.
conclusionChildhood IMNM is characterized by proximal muscle weakness, typical rash, and significantly elevated CK levels, frequently accompanied by anti-SRP or anti-HMGCR antibodies. Early immunosuppressive therapy, including glucocorticoids combined with immunosuppressants or IVIG, may be associated with clinical improvement in this small retrospective series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.